SLC5A2 and cancer: While SGLT2 inhibitors and ARNIs remain investigational in cardio-oncology, no evidence thus far suggests that they interfere with cancer therapy, and emerging data highlight a possible role in protecting against subclinical cardiac injury [141,160].